{"id":69842,"date":"2026-07-13T16:12:35","date_gmt":"2026-07-13T08:12:35","guid":{"rendered":"https:\/\/flcube.com\/?p=69842"},"modified":"2026-07-13T16:12:36","modified_gmt":"2026-07-13T08:12:36","slug":"pfizer-and-astellas-secure-fda-approval-for-padcev-keytruda-combination-as-first-platinum-free-neoadjuvant-adjuvant-therapy-for-muscle-invasive-bladder-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69842","title":{"rendered":"Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) and <strong>Astellas Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4503:TYO\">TYO: 4503<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>PADCEV (enfortumab vedotin-ejfv)<\/strong> in combination with <strong>KEYTRUDA (pembrolizumab or its subcutaneous formulation)<\/strong> as <strong>neoadjuvant and adjuvant treatment<\/strong> for adult patients with <strong>muscle-invasive bladder cancer (MIBC)<\/strong>, regardless of cisplatin eligibility.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Expanded indication approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>PADCEV + KEYTRUDA combination therapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Neoadjuvant and adjuvant treatment for MIBC (all patients, regardless of cisplatin eligibility)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>13 Jul 2026<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>November 2025 (cisplatin-ineligible patients only)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This expanded approval represents a paradigm shift in muscle-invasive bladder cancer treatment, offering the first platinum-free regimen to demonstrate superior outcomes compared to standard-of-care chemotherapy in nearly 25 years.<\/p>\n\n\n\n<h2 id=\"h-clinical-significance-amp-innovation\" class=\"wp-block-heading\">Clinical Significance &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Breakthrough:<\/strong> First platinum-free neoadjuvant\/adjuvant treatment to outperform standard chemotherapy in 25 years<\/li>\n\n\n\n<li><strong>Expanded Patient Access:<\/strong> Now available to all MIBC patients regardless of cisplatin eligibility status<\/li>\n\n\n\n<li><strong>Treatment Paradigm:<\/strong> Combines antibody-drug conjugate (PADCEV) with immune checkpoint inhibitor (KEYTRUDA)<\/li>\n\n\n\n<li><strong>Administration Flexibility:<\/strong> KEYTRUDA available in both intravenous and subcutaneous formulations<\/li>\n\n\n\n<li><strong>Clinical Benefit:<\/strong> Demonstrated improved pathological complete response rates and event-free survival<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Muscle-invasive bladder cancer affects approximately 20,000 patients annually in the United States, with radical cystectomy (bladder removal surgery) remaining the standard curative approach. Neoadjuvant chemotherapy has been the standard pre-surgical treatment, but many patients are ineligible due to renal impairment or other comorbidities.<\/p>\n\n\n\n<h2 id=\"h-global-regulatory-progress\" class=\"wp-block-heading\">Global Regulatory Progress<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Status<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>Full approval granted<\/td><td>July 2026 (expanded); November 2025 (initial)<\/td><\/tr><tr><td><strong>European Union<\/strong><\/td><td>Positive opinion received<\/td><td>May 2026<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>Marketing application submitted<\/td><td>July 2026<\/td><\/tr><tr><td><strong>Other Markets<\/strong><\/td><td>Under review\/planned submissions<\/td><td>Ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The positive European Commission opinion and NMPA submission indicate rapid global regulatory momentum for this combination therapy.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-competitive-landscape\" class=\"wp-block-heading\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Standard of Care Disruption:<\/strong> Challenges decades-long dominance of platinum-based chemotherapy in MIBC<\/li>\n\n\n\n<li><strong>Patient Population Expansion:<\/strong> Addresses significant unmet need in cisplatin-ineligible patients (approximately 50% of MIBC cases)<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> Potential to capture substantial share of $1.2 billion global MIBC treatment market<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Only combination therapy with proven superiority over standard chemotherapy<\/li>\n\n\n\n<li><strong>Pricing Premium:<\/strong> Justified by superior efficacy and expanded patient eligibility<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The combination leverages Pfizer&#8217;s expertise in immuno-oncology (KEYTRUDA) and Astellas&#8217; leadership in antibody-drug conjugates (PADCEV), creating a synergistic therapeutic approach.<\/p>\n\n\n\n<h2 id=\"h-strategic-partnership-dynamics\" class=\"wp-block-heading\">Strategic Partnership Dynamics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Collaboration Structure:<\/strong> Co-development and co-commercialization agreement between Pfizer and Astellas<\/li>\n\n\n\n<li><strong>Revenue Sharing:<\/strong> Equal partnership with shared investment and returns<\/li>\n\n\n\n<li><strong>Geographic Coverage:<\/strong> Global collaboration with coordinated regulatory and commercial strategies<\/li>\n\n\n\n<li><strong>Portfolio Synergy:<\/strong> Complements both companies&#8217; oncology portfolios and strategic priorities<\/li>\n\n\n\n<li><strong>Future Development:<\/strong> Potential expansion into additional indications and combinations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This approval strengthens the strategic alliance between two pharmaceutical giants and validates their collaborative development model.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-context\" class=\"wp-block-heading\">Clinical Development Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Design:<\/strong> Phase III trial comparing PADCEV + KEYTRUDA vs. standard neoadjuvant chemotherapy<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Statistically significant improvement in pathological complete response rate<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Improved event-free survival and overall survival trends<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Manageable toxicity profile consistent with known safety profiles of individual agents<\/td><\/tr><tr><td><strong>Patient Subgroups<\/strong><\/td><td>Consistent benefit observed across cisplatin-eligible and ineligible populations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The robust clinical data supported the FDA&#8217;s decision to expand the indication beyond the initial cisplatin-ineligible population.<\/p>\n\n\n\n<h2 id=\"h-commercial-implications\" class=\"wp-block-heading\">Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Launch:<\/strong> Rapid market access across U.S. treatment centers<\/li>\n\n\n\n<li><strong>Physician Education:<\/strong> Comprehensive training programs on patient selection and treatment protocols<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Strategy<\/th><\/tr><\/thead><tbody><tr><td><strong>Market Access<\/strong><\/td><td>Broad payer coverage leveraging superior clinical outcomes<\/td><\/tr><tr><td><strong>Pricing Strategy<\/strong><\/td><td>Premium pricing reflecting clinical differentiation<\/td><\/tr><tr><td><strong>Sales Force<\/strong><\/td><td>Dedicated teams from both companies supporting launch<\/td><\/tr><tr><td><strong>Patient Support<\/strong><\/td><td>Integrated services for treatment access and adherence<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding product performance, regulatory approvals, and commercial expectations. Actual results may differ due to risks including market competition, reimbursement challenges, and evolving treatment paradigms.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,16,29,863,18,309],"class_list":["post-69842","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-combination-therapy","tag-nyse-pfe","tag-pd-1-l1","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab or its subcutaneous formulation) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69842\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab or its subcutaneous formulation) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69842\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-13T08:12:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-13T08:12:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69842#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69842\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\\\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer\",\"datePublished\":\"2026-07-13T08:12:35+00:00\",\"dateModified\":\"2026-07-13T08:12:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69842\"},\"wordCount\":617,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Combination therapy\",\"NYSE: PFE\",\"PD-1\\\/L1\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69842#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69842\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69842\",\"name\":\"Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\\\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-13T08:12:35+00:00\",\"dateModified\":\"2026-07-13T08:12:36+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab or its subcutaneous formulation) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69842#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69842\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69842#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\\\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab or its subcutaneous formulation) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69842","og_locale":"en_US","og_type":"article","og_title":"Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer","og_description":"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab or its subcutaneous formulation) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility.","og_url":"https:\/\/flcube.com\/?p=69842","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-13T08:12:35+00:00","article_modified_time":"2026-07-13T08:12:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69842#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69842"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer","datePublished":"2026-07-13T08:12:35+00:00","dateModified":"2026-07-13T08:12:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69842"},"wordCount":617,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Combination therapy","NYSE: PFE","PD-1\/L1","Pfizer"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69842#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69842","url":"https:\/\/flcube.com\/?p=69842","name":"Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-13T08:12:35+00:00","dateModified":"2026-07-13T08:12:36+00:00","description":"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab or its subcutaneous formulation) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69842#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69842"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69842#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant\/Adjuvant Therapy for Muscle-Invasive Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69842"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69842\/revisions"}],"predecessor-version":[{"id":69845,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69842\/revisions\/69845"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}